bexarotene has been researched along with methoxsalen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dummer, R; Gellrich, S; Hasan, B; Karrasch, M; Knobler, R; Meulemans, B; Ortiz, P; Ranki, A; Stadler, R; Whittaker, S | 1 |
1 review(s) available for bexarotene and methoxsalen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for bexarotene and methoxsalen
| Article | Year |
|---|---|
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056
Topics: Adolescent; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Early Termination of Clinical Trials; Humans; Infant; Methoxsalen; Middle Aged; Mycosis Fungoides; Photosensitizing Agents; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2012 |